Which patients with localized esophageal adenocarcinoma, if any, would you offer nivolumab after lack of pCR to neoadjuvant FLOT?  

I have not been in such a situation, yet, but I am sure will be soon! My thought will be to start off with patients with a PDL1 score of at least 5. Not sure the degree of path response can predict immune therapy sensitivity, so at this time, I would treat all except the pCR but may also consider li...